Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zymeworks Inc 108 PATRIOT DRIVE SUITE A MIDDLETOWN DE 19709 USA

www.zymeworks.com P: 302-274-8744

Description:

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 603,356
Enterprise Value, $K 445,796
Shares Outstanding, K 70,568
Annual Sales, $ 76,010 K
Annual Net Income, $ -118,670 K
Last Quarter Sales, $ 16,930 K
Last Quarter Net Income, $ -14,480 K
EBIT, $ -138,050 K
EBITDA, $ -127,890 K
60-Month Beta 1.14
% of Insider Shareholders 1.22%
% of Institutional Shareholders 92.89%
Float, K 69,707
% Float 98.78%
Short Volume Ratio 0.71

Growth:

1-Year Return -10.58%
3-Year Return -73.71%
5-Year Return -55.56%
5-Year Revenue Growth 43.36%
5-Year Earnings Growth -36.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 03/06/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -1.74
EPS Growth vs. Prev Qtr 51.22%
EPS Growth vs. Prev Year -104.30%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ZYME Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -26.20%
Return-on-Assets % -20.29%
Profit Margin % -156.12%
Debt/Equity 0.00
Price/Sales 7.95
Price/Cash Flow N/A
Price/Book 1.31
Book Value/Share 6.63
Interest Coverage -0.69
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar